MedTrace Logo

Serum Level of IL-33 in Egyptian Psoriatic Patients

NCT07557095 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2026-04-29

No results posted yet for this study

Summary

This study aimed to compare the serum concentration levels of IL-33 in psoriatic patients undergoing treatment with two commonly prescribed immunosuppressive drugs, methotrexate and cyclosporine. Blood samples will be collected, Serum IL-33 concentrations will be measured using enzyme-linked immunosorbent assay (ELISA) techniques. Clinical assessments, including Psoriasis Area and Severity Index (PASI) scores, will be also recorded to evaluate disease severity and treatment efficacy.

Conditions

  • Egyptian Psoriatic Patients

Interventions

DIAGNOSTIC_TEST

serum interleukin 33 measurement

Blood samples will be collected from participants under aseptic conditions. Serum will be separated and stored appropriately. Serum Interleukin-33 (IL-33) levels will be measured using enzyme-linked immunosorbent assay (ELISA) to evaluate its association with psoriasis.

DIAGNOSTIC_TEST

PASI score

The Psoriasis Area and Severity Index (PASI) is the most widely utilized quantitative tool in clinical dermatology and pharmacological research for grading the severity of chronic plaque psoriasis. It provides a composite score based on the clinical manifestation of the disease across distinct anatomical regions

Sponsors & Collaborators

  • scientific_committee

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-01-01
Completion
2027-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07557095 on ClinicalTrials.gov